JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) marked an important juncture in. BNP in 11, participants without cardiovascular disease in the JUPITER Un Estudio Intervencionista que Evalúa Rosuvastatina (JUPITER, Justification. Desde que en el estudio JUPITER 34 se detectó una mayor incidencia de DM en el grupo con rosuvastatina 35, varios metaanálisis han.

Author: Faet Gogar
Country: Namibia
Language: English (Spanish)
Genre: Photos
Published (Last): 14 March 2010
Pages: 109
PDF File Size: 3.20 Mb
ePub File Size: 14.1 Mb
ISBN: 854-5-81855-595-9
Downloads: 35778
Price: Free* [*Free Regsitration Required]
Uploader: Gut

They are also at very high cardiovascular risk. Clinical trial data and post marketing surveillance have demonstrated important information about rosuvastatin. Very high risk patients or those with severe dyslipidaemia often require combination therapy to achieve treatment goals and enhance lipid profile modification.

Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular Disease

Rosuvastatin in secondary prevention The beneficial effects of statin therapy in patients with ischaemic heart disease are well known. Rosuvastatin is synthetic with a relatively low lipophilicity when compared with other statins and has minimal entry into peripheral cells.

Journal of the American College of Cardiology. Rediscovering bile acid sequestrants. Rosuvastatin in renal disease Advanced kidney disease is associated with high cardiovascular morbidity and death. Table 4 shows the hazard ratios of developing myopathy or liver dysfunction with different statins. Comment in Ann Intern Med.

As with other potent statins, lower doses of rosuvastatin should be used in patients from South East Asia to reduce risk of rhabdomyolysis. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. In this review, we will outline the pharmacology of rosuvastatin; highlight its efficacy and safety.


Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

N Engl J Med. There are no known drug interactions between rosuvastatin and non nucleoside reverse transcriptase inhibitors NNRTIs. Intermittent rosuvastatin Several small studies have reported that alternate-day therapy with rosuvastatin has important benefits in addition to improving the lipid profile. In the United Kingdom, data from the Health Surveys for England suggest that while mortality may be declining, cardiovascular disease morbidity continues to rise.

Rosuvastatina y el estudio JUPITER by Ybel Fermin on Prezi

Drugs affected by co-administration with rosuvastatin. Combination therapy Very high risk patients or those with severe dyslipidaemia often require combination therapy to achieve treatment goals ewtudio enhance lipid profile modification. A possible exception is pitavastatin.

An Assessment of Survival and Cardiovascular Events investigated the effects of rosuvastatin on cardiovascular risk in haemodialysis patients. The mean volume of distribution is litres in steady state. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. Author information Copyright and License information Disclaimer. Penetration of statins into extra-hepatic tissues occurs by passive diffusion and is dependent on their lipophilicity.

The risk was higher in older participants of the statin trials.

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. A number of reports are emerging about intermittent or pulsed therapy which is better tolerated yet maintains reasonable lipid control.


Previously, there has been limited data on statin benefits in women, black and Hispanic patients. Subsequent meta-analysis of clinical trials and post marketing experience have consistently shown that rosuvastatin has a comparable safety profile to other available statins when rosuvasttatina at 10 mg to 40 mg daily dose.

HIV patients on highly active antiretroviral therapy are increasingly found to have hypercholesterolaemia and hypertriglyceridaemia. ApoA-1 ratio as an important predictor of myocardial infarction. The drive towards more stringent goals for LDL-C lowering in cardiovascular risk prevention has brought high impact statin therapy into focus. This is the only statin rosuvastatin has been shown to reduce cardiovascular and all cause mortality.

Rosuvastaatina in patients with type 2 diabetes mellitus undergoing hemodialysis. In the same study rosuvastatin 20 mg achieved similar LDL-C reduction as atorvastatin 80 mg. Implications of the Justification for Use of Statins in Prevention: